FDA Issues Black Box Warning for Diabetes Drug Invokana

FDA Issues Strongest Warning for Invokana

FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)

FDA Issues Black Box Warning

Based on new data from two large clinical trials, the U.S. Food and Drug Administration (FDA) has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.

If you or a loved one have been taking Invokana (Invokamet, Invokamet XR) and have suffered serious side effects or permanent disability, including amputation, please contact MedRecallNews today to get the help you need.

Learn More

 

Leave a Reply

Your email address will not be published. Required fields are marked *